This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Drmanac, S. Articles by Malloy, M. J. Search for Related Content PubMed PubMed Citation Articles by Drmanac, S. Articles by Malloy, M. J. Social Bookmarking                         What's this?

Elevated Baseline Triglyceride Levels Modulate Effects of HMGCoA Reductase Inhibitors on Plasma Lipoproteins

Hyseq, Inc., Sunnyvale, CA

D. C. Heilbron, PhD

C.R. Pullinger, PhD

Cardiovascular Research Institute, University of California, San Francisco, CA

M. Jafari, Pharm D

Western University of Health Sciences, Pomona, CA

D. Gietzen

T. Ukrainczyk

Hyseq, Inc., Sunnyvale, CA

M. H. Cho

P. H. Frost, MD

K. Siradze, MD

Cardiovascular Research Institute, University of California, San Francisco, CA

R. T. Drmanac, PhD

Hyseq, Inc., Sunnyvale, CA

J. P. Kane, MD, PhD

M. J. Malloy, MD

Cardiovascular Research Institute, University of California, San Francisco, CA

Background: The response in levels of very-low-density (VLDL) and low-density (LDL) lipoproteins varies substantially among hyperlipidemic patients during treatment with HMGCoA reductase inhibitors. Apolipoprotein E genotype and gender are known to contribute to the regulation of steady state levels of plasma lipoproteins. This study explores the effect of these and other potential determinants of the response of VLDL and LDL to treatment with reductase inhibitors.

Methods: Using mixed linear statistical models, the response of lipoprotein lipid values was studied in 142 hyperlipidemic individuals who were treated with reductase inhibitors. Patients received one or more of the following drugs individually for a total of 623 treatment observations: lovastatin, pravastatin, simvastatin, or atorvastatin. For evaluation of the effects of treatment in the aggregate, actual doses were expressed as equivalent doses of atorvastatin, using factors based on random assignment comparisons in 16 reported studies. The analysis factors considered were apolipoprotein E genotype, baseline average triglycerides >170 mg/dL (vs less), and gender.

Results: Presence of an apo e4 allele was associated with a trend toward greater reduction of triglyceride levels and a diminished ability of the reductase inhibitors to reduce LDL cholesterol levels. Gender had only minimal effect on the response of either LDL cholesterol or triglycerides. However, the effect of elevated baseline triglycerides on the response of both triglycerides and LDL cholesterol was striking and was exerted in opposite directions. The triglyceride-lowering effect of reductase inhibitors was greater in patients with initial triglyceride levels above 170 mg/dL (P=0.0001). The effect was even greater in patients with initial triglyceride levels over 250 mg/dL (P=0.015). Conversely, for LDL cholesterol levels, elevated baseline triglycerides were associated with a significantly decreased response to the drugs (P=0.0015).

Conclusions: These findings indicate that baseline triglyceride levels are an important predictor of response of plasma lipoproteins to HMGCoA reductase inhibitors, perhaps reflecting fundamental differences in mechanism underlying the hyperlipidemic phenotype.

Key Words: apo E genotype • low-density lipoproteins • very-low-density lipoproteins

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 6, No. 1, 47-56 (2001)
DOI: 10.1177/107424840100600106


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T.B. Twickler, G.M. Dallinga-Thie, J.S. Cohn, and M.J. Chapman Elevated Remnant-Like Particle Cholesterol Concentration: A Characteristic Feature of the Atherogenic Lipoprotein Phenotype Circulation, April 27, 2004; 109(16): 1918 - 1925. [Full Text] [PDF]